<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Chemoprevention with the <z:chebi fb="0" ids="51349">polyamine</z:chebi>-inhibitory regimen difluoromethylornithine (DFMO) + <z:chebi fb="0" ids="9352">sulindac</z:chebi> markedly reduces risk of recurrent <z:mpath ids='MPATH_270'>adenoma</z:mpath> in colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> patients </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is associated with risk of colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This study investigates how <z:hpo ids='HP_0001513'>obesity</z:hpo> influences risk of recurrent <z:mpath ids='MPATH_270'>adenoma</z:mpath> after prolonged treatment with DFMO + <z:chebi fb="0" ids="9352">sulindac</z:chebi> versus placebo </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Our analysis included subjects enrolled in the phase III colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> prevention clinical trial investigating DFMO + <z:chebi fb="0" ids="9352">sulindac</z:chebi> versus placebo </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were classified by <z:hpo ids='HP_0001513'>obesity</z:hpo> (body mass index, BMI ≥ 30 kg/m(2)) status at baseline </plain></SENT>
<SENT sid="5" pm="."><plain>Pearson χ(2) statistic and Mann-Whitney U test were used to compare baseline characteristics, including rectal tissue <z:chebi fb="0" ids="51349">polyamine</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>Log-binomial regression analysis was used to determine the risk ratio (RR) of recurrent <z:mpath ids='MPATH_270'>adenomas</z:mpath>, adjusted for covariates and an interaction term for <z:hpo ids='HP_0001513'>obesity</z:hpo> and treatment </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The final analytic cohort was comprised of 267 patients </plain></SENT>
<SENT sid="8" pm="."><plain>In separate regression models, the risk of <z:mpath ids='MPATH_270'>adenoma</z:mpath> recurrence after treatment compared to placebo was similar for <z:mp ids='MP_0001261'>obese</z:mp> (RR = 0.32, 95 % CI 15-71) and non-<z:mp ids='MP_0001261'>obese</z:mp> patients (RR = 0.27, 95 % CI 15-49) </plain></SENT>
<SENT sid="9" pm="."><plain>No significant interaction was detected between <z:hpo ids='HP_0001513'>obesity</z:hpo>, treatment, and risk of colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> in the full regression model (p (interaction) = 0.91) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0001513'>Obesity</z:hpo> does not substantially modify the colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> risk reduction ascribed to DFMO + <z:chebi fb="0" ids="9352">sulindac</z:chebi> versus placebo </plain></SENT>
</text></document>